Healthcare Industry News: neurodegenerative
News Release - November 14, 2012
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer'sLA JOLLA, Calif., Nov. 14, 2012 -- (Healthcare Sales & Marketing Network) -- StemGenex™, Inc. -- November is National Alzheimer's Disease Awareness Month and is dedicated to raising the awareness of this neurodegenerative disorder. Alzheimer's currently affects 5 million people in the U.S. and 35 million across the globe, and due to aging populations, this number is growing rapidly.
Currently pharmacological treatments only manage symptoms and offer no cure for the disease. Alternatively, adult stem cells have shown great promise to potentially replace lost or support damaged brain cells due to their remarkable ability of differentiating into many cell types.
StemGenex, a U.S. based company, is pioneering new therapeutic methods for adipose-derived adult stem cells. StemGenex has a major emphasis on Alzheimer's disease and other conditions such as Parkinson's, COPD, Multiple Sclerosis and Type 1 Diabetes. For over 6 years StemGenex has been conducting studies to advance Alzheimer's adult stem cell treatment protocols in efforts to alleviate the disease's symptoms. Some innovations at StemGenex include:
- A proprietary 'Double Activation Process' which increases both the viability and the quantity of stem cells that are received in an application.
- Development of non-invasive methods for encouraging stem cells to cross the blood-brain barrier.
Patients receiving treatment are reporting an alleviation of their symptoms which include:
- Better completion of normal tasks
- Verbal communication
We are on the brink of some tremendously exciting discoveries and developments in the use of adult stem cell based-therapies, for the treatment of Alzheimer's disease. Also, since adult stem cells can be isolated from an individual's own fat tissue there are no ethical or religious controversies.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.